ArticleHealth affairs scholar2026
Opioid use disorder medication treatment in residential settings increased 2017-2021, but sustaining it following stays remains an issue.
Article in Health affairs scholar, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Introduction: Residential treatment is part of the care continuum for opioid use disorder (OUD). However, use of OUD medications (MOUD) has been historically low in this setting. The goal of this study was to assess changes in MOUD during residential treatment stays and the 12-month period surrounding them. Methods: We used national Medicaid claims data for the year 2017-2021 and descriptive as well as regression analyses. Results: Between 2017 and 2021, the rate of MOUD treatment in residential settings increased from 30.4 to 58.5 percentage points. By contrast, the rate of MOUD treatment 6 months before residential treatment stays and 5 months following residential treatment stays was low in 2017 and increased only slightly. Changes were similar in states that implemented a substance use disorder waiver compared to non-waiver states. Most states exhibited similar changes. New York was the only state where MOUD rates before and after residential treatment stays increased markedly. Conclusions: Our study suggests that use of MOUD during residential treatment stays increased substantially 2017-2021, but that this increase was not sustained during the months following stays. Improving retention in MOUD treatment following residential treatment stays could be an important future policy goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.